Previous 10 | Next 10 |
Chembio Diagnostics (NASDAQ:CEMI) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close. The consensus EPS Estimate is -$0.20 (+42.9% Y/Y) and the consensus Revenue Estimate is $13.55M (+32.6% Y/Y). Over the last 1 year, CEMI has beaten EPS estimates 25% of t...
ACR, AQN, AVAV, AVGO, BCEL, CEMI, CLLS, CLXT, COO, COST, OTCPK:CURLF, DBVT, DUOL, EGLE, ENVX, EOLS, ESTC, EVFM, FCRD, FDUS, FNKO, GPS, INMB, OTCPK:MEGEF, MRVL, NCMI, ONCY, PAYO, PBYI, SIGA, SWBI, VERI, VZIO For Seeking Alpha's full earnings season calendar, click here. For further details s...
HAUPPAUGE, N.Y., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2021 after the close of tradin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let’s start off the day right with a look into the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Loads of penny stocks are on the move today and we...
HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately. “...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +37%. Takung Art (NYSE:TKAT) +34%. ShiftPixy (NASDAQ:PIXY) +37%. Pop Culture (NASDAQ:CPOP) +36%. Insignia Systems (NASDAQ:ISIG) +19%. Siyata (NASDAQ:SYTA) +16%. Calix (NYSE:CALX) +15%. WISeKey (NASDAQ:WKEY) +12%. Biofrontera (NASDAQ:BFRI) +13%. Law...
Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...
Applied UV (NASDAQ:AUVI) -22% on pricing $8.0 million public offering Chembio Diagnostics (NASDAQ:CEMI) -21% after FDA declined to review EUA application for COVID/Flu test. FuelCell Energy (NASDAQ:FCEL) -14% on Q4 earnings release. PyroGenesis Canada (NASDAQ:PYR...
Chembio Diagnostics (NASDAQ:CEMI) down 20% premarket after the FDA notified the company that it was declining to review its application for an emergency use authorization (EUA) for the DPP Respiratory Antigen Panel. The Agency informed CEMI that, in order to proceed, the company wil...
Chembio Diagnostics (NASDAQ:CEMI) has submitted a De Novo/510(k) Request to the FDA for DPP SARS-CoV-2 Antigen test system. Shares down 1.7% premarket at $1.73. Chembio received an award from the BARDA to support development of a COVID-19 point-of-care antigen test system using its ...
News, Short Squeeze, Breakout and More Instantly...
Chembio Diagnostics Inc. Company Name:
CEMI Stock Symbol:
NASDAQ Market:
Chembio Diagnostics Inc. Website:
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of ...
MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 ...
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 ...